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The discovery of antibody-mediated catalysis was a breakthrough that showed antibody function is not 
limited to specific binding interactions, and that immunoglobulins (Igs) may also chemically transform 
their target antigens. Recently, so-called “natural catalytic antibodies” have been intimately linked 
with several pathologies, where they either protect the organism or contribute to the development of 
autoimmune abnormalities. Previously, we showed that myelin-reactive autoantibodies from patients 
with multiple sclerosis (MS) and mice with experimental autoimmune encephalomyelitis (EAE) exhibit 
the ability to recognize and hydrolyse distinct epitopes within myelin basic protein (MBP). Further, 
the antibody-mediated cleavage of encephalitogenic MBP peptide 81–103, flanked by two fluorescent 
proteins, can serve as a novel biomarker for MS. Here, we report the next generation of this biomarker, 
based on the antibody-mediated degradation of a novel chemically synthesized FRET substrate, 
comprising the fluorophore Cy5 and the quencher QXL680, interconnected by the MBP peptide 81–99: 
Cy5-MBP81–99-QXL680. This substrate is degraded upon incubation with either purified antibodies from 
MS patients but not healthy donors or purified antibodies and splenocytes from EAE but not from 
non-immunized mice. Data presented herein suggest the elaboration of potential specific, rapid, and 
sensitive diagnostic criteria of active progressive MS.
B cells contribute to the immune response via presentation of antigens, release of various cytokines, secretion of 
antibodies and also may have immunosuppression functions1. In turn, the major functions of antibodies, pro-
duced by B cells, include pathogen neutralization, antibody-mediated phagocytosis, antibody-dependent cellular 
cytotoxicity, and complement-mediated lysis of pathogens and infected cells2. In addition to these functions, the 
catalytic activity of immunoglobulins is elevated during pre-B-cell acute lymphoid leukaemia, acute myeloid leu-
cosis, acquired immune deficiency syndrome3, infections4,5, and, especially, autoimmune disorders6–9. In contrast 
to the dozens of chemical reactions catalysed by artificial catalytic antibodies10–12, natural catalytic antibodies 
were initially shown to exhibit limited hydrolysis ability (restricted to amide13 and phosphodiester6 bonds); how-
ever, numerous alternative activities were further observed14–17. Therefore, the hydrolysing activity of antibodies 
may be important in their function, either in host defence or autoimmune progression18.
One of the most socially significant autoimmune diseases worldwide is multiple sclerosis (MS). This disease 
is characterized by chronic inflammation, demyelination, axonal loss, and oligodendrocyte loss; it is caused by 
activation and migration of immune cells, such as T cells, B cells, and macrophages, into the central nervous 
system (CNS)19. Early diagnosis is necessary for successful MS treatment. Although the diagnosis of MS is based 
predominantly on clinical and magnetic resonance imaging (MRI) findings, a variety of para-clinical laboratory 
tests can support clinical observations20,21. Since 2005, MRI of CNS has been widely used for MS diagnosis, fol-
lowing the so-called McDonald Criteria21,22. Concomitantly, biochemical and immunological diagnostic mark-
ers continue to undergo development. These include (i) detection of intrathecal synthesis of oligoclonal bands 
and quantitative IgG index23,24; (ii) an elevated titre of autoantibodies25 and (iii) cytokine levels26,27. Previously, 
we developed a diagnostic marker for MS based on the ability of serum autoantibodies from experimental 
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